On October 20, 2021 OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, reported four presentations at the upcoming 2021 International Oncolytic Virus Conference (IOVC) being held November 5-7, 2021, both virtually and in Sedona, Ariz (Press release, OncoMyx Therapeutics, OCT 20, 2021, View Source [SID1234591591]). The company plans to present recent preclinical data demonstrating oncolytic activity, transgene production, immunomodulatory mechanisms of action, and efficacy of intratumoral (IT) and intravenous (IV) administration of OncoMyx’s multi-armed myxoma virotherapy for the treatment of cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
OncoMyx Talk and Poster Info
Session 1: Novel Payloads and Mechanisms of Action 1 with Leslie Sharp, PhD, CSO, will happen Friday, Nov. 5th from 8:55am – 9:20am MST
Poster Presentation (Virtual) with Lina Franco, PhD, Scientist II, is available on demand Friday, Nov. 5th – Sunday, Nov. 7th
A Special Session with Steve Potts, PhD, MBA, CEO and cofounder, entitled "Benefits of a systemic-delivered, multi-armed non-human pathogen, myxoma virus, against solid and heme cancers" will take place Saturday, Nov. 6th from 8:44pm – 8:56pm MST.
A Live Q&A for the poster presentation with Dr. Franco will be held Sunday, Nov. 7th from 1:00pm – 3:30pm MST.
The poster will be available on OncoMyx’s website on November 5th.
About Oncolytic Immunotherapy and Myxoma Virus
Oncolytic viruses (OV) selectively replicate in and lyse tumor cells and provide stimulation to the immune system, representing a promising therapeutic option in development to treat cancers that do not respond well to treatment with immune checkpoint inhibitors. Myxoma virus (MYXV) is a member of the Pox family of double stranded DNA viruses. The natural host of MYXV is a subset of rabbits and hares, but MYXV is able to infect cancer cell lines of humans and other species. The genome of MYXV is relatively large and is amenable to engineering for expression of transgenic proteins, making it an excellent oncolytic virus for introduction of immunomodulatory proteins.